Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including mortality, in the largest safety study ever performed comparing hydroxychloroquine treatment to hydroxychloroquine and azithromycin treatment for rheumatoid arthritis patients.

variety of capsule pills in packages

Hydroxychloroquine is commonly used to treat rheumatoid arthritis, while azithromycin is a frequently-prescribed antibiotic to treat infections such as pneumonia, chest and sinus infections, etc. This network study, led by the Observational Health Data Sciences and Informatics (OHDSI) community, was recently published in Lancet Rheumatology.

In patients with rheumatoid arthritis, hydroxychloroquine treatment in the short term (30 days) was found to not carry excess risk of complications associated with its use, but hydroxychloroquine treatment in the long term had a 65% relative increase in cardiovascular-related mortality, compared to sulfasalazine, a similar rheumatoid arthritis drug.

Hydroxychloroquine and azithromycin together had a cardiovascular mortality risk that was more than twice (2.19) as high as the comparative treatment even in the short term based on findings from more than 320,000 users of that combination therapy. This treatment also produced a 15-20% increased rate of angina/chest pain and heart failure.

The full story is available on the University of Oxford website

Similar stories

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

New tool aims to make bowel cancer treatments more effective

The Leedham Lab in Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Radcliffe Department of Medicine's Professor Higgs major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.

First evidence drug resistant bacteria can travel from gut to lung, increasing infection risks

A new Oxford University study released during World Antimicrobial Awareness Week has significant findings on how antimicrobial resistance (AMR) arises and persists. The results, published today in Nature Communications, provide the first direct evidence of AMR bacteria migrating from a patient’s gut microbiome to the lungs, increasing the risk of deadly infections.